文献速递骨软组织肉瘤与黑色素瘤

达拉非尼联合曲美替尼新辅助治疗III期黑色素瘤的五年分析

Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.
PubMed 文献 · Ann Oncol · 2024-05-14

NeoCombi II期单臂试验纳入35例可切除的IIIB-C期BRAF V600E/K突变黑色素瘤患者,接受达拉非尼联合曲美替尼治疗52周并于第12周行完整切除。5年无复发生存率40%,无远处转移生存率57%,总生存率80%;病理完全缓解者无复发生存率53% vs 非病理完全缓解者28%(P=0.087)。

要点

  • 5年无复发生存率40%,无远处转移生存率57%,总生存率80%。
  • 病理完全缓解者5年无复发生存率53% vs 非病理完全缓解者28%(P=0.087)。
  • 病理完全缓解者仍有较高复发风险,与免疫治疗不同。

核心结论

  • 新辅助达拉非尼联合曲美替尼在临床III期黑色素瘤中病理缓解率高,但无复发生存率低,与单独辅助靶向治疗相似。
  • 对达拉非尼联合曲美替尼达到病理完全缓解的患者仍有高复发风险,不同于免疫治疗中复发罕见。

研究设计与样本

  • NeoCombi(NCT01972347)是一项单臂、开放标签、单中心、II期试验。
  • 纳入35例成人(年龄≥18岁)组织学确认、可切除、RECIST可测量、美国癌症联合委员会第七版临床IIIB-C期BRAF V600E/K突变黑色素瘤且ECOG体能状态≤1的患者。
  • 患者接受52周达拉非尼150 mg口服每日两次联合曲美替尼2 mg口服每日一次治疗,第12周对治疗前瘤床行完整切除。

主要发现

  • 2014年8月20日至2017年4月19日入组35例患者,数据截止2021年8月17日,中位随访60个月(95%CI 56-72个月)。
  • 35例中21例(60%)复发,其中12例(57%)首次复发位于局部区域(随后6例出现远处复发),9例(43%)首次复发位于远处,包括3例脑转移。
  • 多数复发发生在2年内,3年后无复发。
  • 5年时无复发生存率40%(95%CI 27%-60%),无远处转移生存率57%(95%CI 42%-76%),总生存率80%(95%CI 67%-94%)。
  • 按病理反应分层:病理完全缓解者5年无复发生存率53% vs 非病理完全缓解者28%(P=0.087),无远处转移生存率59% vs 55%(P=0.647),总生存率88% vs 71%(P=0.205)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report 5-year outcomes from the phase II NeoCombi trial. PATIENTS AND METHODS: NeoCombi (NCT01972347) was a single-arm, open-label, single-centre, phase II trial. Eligible patients were adults (aged ≥18 years) with histologically confirmed, resectable, RECIST-measurable, American Joint Committee on Cancer seventh edition clinical stage IIIB-C BRAF V600E/K-mutant melanoma and Eastern Cooperative Oncology Group performance status ≤1. Patients received 52 weeks of treatment with dabrafenib 150 mg (orally twice per day) plus trametinib 2 mg (orally once per day), with complete resection of the pre-therapy tumour bed at week 12. RESULTS: Between 20 August 2014 and 19 April 2017, 35 patients were enrolled. At data cut-off (17 August 2021), the median follow-up was 60 months [95% confidence interval (CI) 56-72 months]. Overall, 21 of 35 (60%) patients recurred, including 12 (57%) with first recurrence in locoregional sites (followed by later distant recurrence in 6) and 9 (43%) with first recurrence in distant sites, including 3 in the brain. Most recurrences occurred within 2 years, with no recurrences beyond 3 years. At 5 years, recurrence-free survival (RFS) was 40% (95% CI 27% to 60%), distant metastasis-free survival (DMFS) was 57% (95% CI 42% to 76%), and overall survival was 80% (95% CI 67% to 94%). Five-year survival outcomes were stratified by pathological response: RFS was 53% with pathological complete response (pCR) versus 28% with non-pCR (P = 0.087), DMFS was 59% versus 55% (P = 0.647), and overall survival was 88% versus 71% (P = 0.205), respectively. CONCLUSIONS: Neoadjuvant dabrafenib plus trametinib has high pathological response rates in clinical stage III melanoma, but low rates of RFS, similar to those achieved with adjuvant targeted therapy alone. Patients with a pCR to dabrafenib plus trametinib still had a high risk of recurrence, unlike that seen with immunotherapy where recurrences are rare.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Menzies AM, Lo SN, Saw RPM, et al. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Ann Oncol. 2024. PMID: 38754780. doi:10.1016/j.annonc.2024.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。